Liquid Biopsy Reduces Chemotherapy in Stage II Colon Cancer Without Compromising Outcomes
Chicago—Use of circulating tumor DNA (ctDNA) as a treatment decision tool in colon cancer can spare many patients the need for adjuvant chemotherapy, according to findings from a phase 2 trial.
Results of the DYNAMIC (Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage II Colon Cancer) trial were presented at the 2022 annual meeting of the American Society of Clinical Oncology